Literature DB >> 16510747

Circumferential pulmonary-vein ablation for chronic atrial fibrillation.

Hakan Oral1, Carlo Pappone, Aman Chugh, Eric Good, Frank Bogun, Frank Pelosi, Eric R Bates, Michael H Lehmann, Gabriele Vicedomini, Giuseppe Augello, Eustachio Agricola, Simone Sala, Vincenzo Santinelli, Fred Morady.   

Abstract

BACKGROUND: We conducted a randomized, controlled trial of circumferential pulmonary-vein ablation for the treatment of chronic atrial fibrillation.
METHODS: A total of 146 patients with a mean (+/-SD) age of 57+/-9 years who had chronic atrial fibrillation were randomly assigned to receive amiodarone and undergo two cardioversions during the first three months alone (the control group) or in combination with circumferential pulmonary-vein ablation. Cardiac rhythm was assessed with daily telephonic transmissions for one year. The left atrial diameter and the severity of symptoms were assessed at 12 months.
RESULTS: Among the 77 patients assigned to undergo circumferential pulmonary-vein ablation, ablation was repeated because of recurrent atrial fibrillation in 26 percent of patients and atypical atrial flutter in 6 percent. An intention-to-treat analysis showed that 74 percent of patients in the ablation group and 58 percent of those in the control group were free of recurrent atrial fibrillation or flutter without antiarrhythmic-drug therapy at one year (P=0.05). Among the 69 patients in the control group, 53 (77 percent) crossed over to undergo circumferential pulmonary-vein ablation for recurrent atrial fibrillation by one year and only 3 (4 percent) were in sinus rhythm without antiarrhythmic-drug therapy or ablation. There were significant decreases in the left atrial diameter (12+/-11 percent, P<0.001) and the symptom severity score (59+/-21 percent, P<0.001) among patients who remained in sinus rhythm after circumferential pulmonary-vein ablation. Except for atypical atrial flutter, there were no complications attributable to circumferential pulmonary-vein ablation.
CONCLUSIONS: Sinus rhythm can be maintained long term in the majority of patients with chronic atrial fibrillation by means of circumferential pulmonary-vein ablation independently of the effects of antiarrhythmic-drug therapy, cardioversion, or both. The maintenance of sinus rhythm is associated with a significant decrease in both the severity of symptoms and the left atrial diameter. Copyright 2006 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16510747     DOI: 10.1056/NEJMoa050955

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  214 in total

1.  [Studies on the energy for sperm motility (author's transl)].

Authors:  K Imamura
Journal:  Nihon Funin Gakkai Zasshi       Date:  1975-10

2.  NT-proBNP, but not ANP and C-reactive protein, is predictive of paroxysmal atrial fibrillation in patients undergoing pulmonary vein isolation.

Authors:  Jinqi Fan; Hua Cao; Li Su; Zhiyu Ling; Zengzhang Liu; Xianbin Lan; Yanping Xu; Weijie Chen; Yuehui Yin
Journal:  J Interv Card Electrophysiol       Date:  2011-09-21       Impact factor: 1.900

3.  Efficacy of pulmonary vein isolation with a novel hot balloon ablation catheter.

Authors:  Rudolph F Evonich; David M Nori; David E Haines
Journal:  J Interv Card Electrophysiol       Date:  2012-01-08       Impact factor: 1.900

4.  Recurrent atrial flutter and fibrillation in pregnancy.

Authors:  Charly J Sengheiser; Kevin C Channer
Journal:  BMJ Case Rep       Date:  2011-06-03

Review 5.  Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities.

Authors:  Michiel Rienstra; Steven A Lubitz; Saagar Mahida; Jared W Magnani; João D Fontes; Moritz F Sinner; Isabelle C Van Gelder; Patrick T Ellinor; Emelia J Benjamin
Journal:  Circulation       Date:  2012-06-12       Impact factor: 29.690

Review 6.  Can ablation prevent the excess mortality of atrial fibrillation?

Authors:  Elad Anter; David J Callans
Journal:  Curr Cardiol Rep       Date:  2010-09       Impact factor: 2.931

7.  Effect of K201, a novel antiarrhythmic drug on calcium handling and arrhythmogenic activity of pulmonary vein cardiomyocytes.

Authors:  Y-J Chen; Y-C Chen; W Wongcharoen; C-I Lin; S-A Chen
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

8.  Catheter Ablation of Atrial Fibrillation: Advent of Second-Generation Technologies.

Authors:  Eric Buch; Kalyanam Shivkumar
Journal:  J Am Coll Cardiol       Date:  2015-09-22       Impact factor: 24.094

Review 9.  Evidence-based approach to ablating atrial fibrillation.

Authors:  Takumi Yamada; G Neal Kay
Journal:  Curr Cardiol Rep       Date:  2007-09       Impact factor: 2.931

Review 10.  Catheter ablation versus medical therapy for patients with persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized controlled trials.

Authors:  Chen Chen; Xinbin Zhou; Min Zhu; Shenjie Chen; Jie Chen; Hongwen Cai; Jin Dai; Xiaoming Xu; Wei Mao
Journal:  J Interv Card Electrophysiol       Date:  2018-03-16       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.